The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction

Journal of Hepatology

Volumn 66, Issue 4, 2017, Pages 724-733

  Schwabl, Philipp ^a   Hambruch, Eva ^b   Seeland, Berit A ^a   Hayden, Hubert ^a   Wagner, Michael ^a   Garnys, Lukas ^a   Strobel, Bastian ^a   Schubert, Tim Lukas ^a   Riedl, Florian ^a   Mitteregger, Dieter ^c   Burnet, Michael ^d   Starlinger, Patrick ^a   Oberhuber, Georg ^a   Deuschle, Ulrich ^b   Rohr Udilova, Nataliya ^a   Podesser, Bruno K ^a   Peck Radosavljevic, Markus ^a   Reiberger, Thomas ^a   Kremoser, Claus ^b   Trauner, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PHENEX PHARMACEUTICALS AG   (Germany)

^c Group Practice LABORSat   (Austria)

^d Synovo GmbH   (Germany)

Author keywords

Bacterial translocation; Cirrhosis; Farnesoid X receptor; Fibrosis; FXR agonist; Intestinal permeability; Mouse; Portal hypertension; PX20606; Rat

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AMINOTRANSFERASE; ANGIOPOIETIN; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 1A1; CYSTATHIONINE GAMMA LYASE; DIMETHYLAMINOHYDROLASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HORMONE RECEPTOR STIMULATING AGENT; HYDROLASE; HYDROXYPROLINE; LIPOPOLYSACCHARIDE BINDING PROTEIN; MOESIN; OBETICHOLIC ACID; PLATELET DERIVED GROWTH FACTOR; PX 20606; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR; 4-(2-(2-CHLORO-4-((5-CYCLOPROPYL-3-(2,6-DICHLOROPHENYL)-4-ISOXAZOLYL)METHOXY)PHENYL)CYCLOPROPYL)BENZOIC ACID; BENZOIC ACID DERIVATIVE; BILE ACID; BILIRUBIN; CELL RECEPTOR; CHOLESTEROL; FARNESOID X-ACTIVATED RECEPTOR; ISOXAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL TRANSLOCATION; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER SINUSOID; MACROPHAGE; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; VASCULAR REMODELING; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION; VEIN LIGATION; AGONISTS; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CAPILLARY; DISEASE MODEL; DRUG EFFECTS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BENZOATES; BILE ACIDS AND SALTS; BILIRUBIN; CAPILLARIES; CHOLESTEROL; DISEASE MODELS, ANIMAL; HYPERTENSION, PORTAL; ISOXAZOLES; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; VASCULAR REMODELING; VASCULAR RESISTANCE;

EID: 85010966335     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.12.005     Document Type: Article

References (63)

1. [1] Trautwein, C., Friedman, S.L., Schuppan, D., Pinzani, M., Hepatic fibrosis: Concept to treatment. J Hepatol 62 (2015), S15–S24.
2. [2] Mandorfer, M., Kozbial, K., Schwabl, P., et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 65 (2016), 692–699.
3. [3] Tsochatzis, E., Bruno, S., Isgro, G., et al. Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. J Hepatol 60 (2014), 948–954.
4. [4] Kim, M.Y., Cho, M.Y., Baik, S.K., et al. Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 55 (2011), 1004–1009.
5. [5] Ripoll, C., Groszmann, R., Garcia-Tsao, G., et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133 (2007), 481–488.
6. [6] Gupta, T.K., Toruner, M., Chung, M.K., Groszmann, R.J., Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28 (1998), 926–931.
7. [7] Pinzani, M., Milani, S., de Franco, R., et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 110 (1996), 534–548.
8. [8] Wiest, R., Groszmann, R.J., The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35 (2002), 478–491.
9. [9] Jalan, R., Fernandez, J., Wiest, R., et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 60 (2014), 1310–1324.
10. [10] Reiberger, T., Ferlitsch, A., Payer, B.A., et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 58 (2013), 911–921.
11. [11] Schwabl, P., Bucsics, T., Soucek, K., et al. Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. Liver Int 35 (2015), 2121–2128.
12. [12] de Franchis, R., Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 53 (2010), 762–768.
13. [13] Peck-Radosavljevic, M., Angermayr, B., Datz, C., et al. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr 125 (2013), 200–219.
14. [14] Reiberger, T., Ulbrich, G., Ferlitsch, A., et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 62 (2013), 1634–1641.
15. [15] Sersté, T., Melot, C., Francoz, C., et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52 (2010), 1017–1022.
16. [16] Mandorfer, M., Bota, S., Schwabl, P., et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 146 (2014), 1680–1690, e1.
17. [17] Higashiyama, H., Kinoshita, M., Asano, S., Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray. Acta Histochem 110 (2008), 86–93.
18. [18] Wagner, M., Zollner, G., Trauner, M., Nuclear receptors in liver disease. Hepatology 53 (2011), 1023–1034.
19. [19] Halilbasic, E., Claudel, T., Trauner, M., Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 58 (2013), 155–168.
20. [20] Trauner, M., Halilbasic, E., Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 140 (2011), 1120–1125.
21. [21] Kong, B., Luyendyk, J.P., Tawfik, O., Guo, G.L., Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 328 (2009), 116–122.
22. [22] Wu, W.B., Chen, Y.Y., Zhu, B., et al. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice. Biochimie 115 (2015), 86–92.
23. [23] Modica, S., Petruzzelli, M., Bellafante, E., et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142 (2012), 355–365, e1–e4.
24. [24] Baghdasaryan, A., Claudel, T., Gumhold, J., et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO-3 output. Hepatology 54 (2011), 1303–1312.
25. [25] Zhang, S., Wang, J., Liu, Q., Harnish, D.C., Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 51 (2009), 380–388.
26. [26] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
27. [27] Degirolamo, C., Rainaldi, S., Bovenga, F., Murzilli, S., Moschetta, A., Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 7 (2014), 12–18.
28. [28] Sayin, S.I., Wahlström, A., Felin, J., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17 (2013), 225–235.
29. [29] Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E., Fiorucci, S., The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183 (2009), 6251–6261.
30. [30] Gadaleta, R.M., van Erpecum, K.J., Oldenburg, B., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60 (2011), 463–472.
31. [31] Inagaki, T., Moschetta, A., Lee, Y., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103 (2006), 3920–3925.
32. [32] Lutz, P., Berger, C., Langhans, B., et al. A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis. Dig Liver Dis 46 (2014), 1047–1050.
33. [33] Lorenzo-Zúñiga, V., Bartolí, R., Planas, R., et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 37 (2003), 551–557.
34. [34] Verbeke, L., Farre, R., Verbinnen, B., et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol 185 (2015), 409–419.
35. [35] Wang, Y., Chen, W., Wang, M., Yu, D., Forman, B.M., Huang, W., Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48 (2008), 1632–1643.
36. [36] Gadaleta, R.M., Oldenburg, B., Willemsen, E.C., et al. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine. Biochim Biophys Acta 1812 (2011), 851–858.
37. [37] Zhang, S., Liu, Q., Wang, J., Harnish, D.C., Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem Biophys Res Commun 379 (2009), 476–479.
38. [38] Li, J., Wilson, A., Kuruba, R., et al. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res 77 (2008), 169–177.
39. [39] Li, Y.T.Y., Swales, K.E., Thomas, G.J., Warner, T.D., Bishop-Bailey, D., Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 27 (2007), 2606–2611.
40. [40] Verbeke, L., Farre, R., Trebicka, J., et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59 (2014), 2286–2298.
41. [41] Mookerjee, R.P., Mehta, G., Balasubramaniyan, V., et al. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J Hepatol 62 (2015), 325–331.
42. [42] Renga, B., Mencarelli, A., Migliorati, M., Distrutti, E., Fiorucci, S., Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. World J Gastroenterol 15 (2009), 2097–2108.
43. [43] Li, J., Kuruba, R., Wilson, A., Gao, X., Zhang, Y., Li, S., Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand. PLoS One, 5, 2010, e13955.
44. [44] Úbeda, M., Lario, M., Muñoz, L., et al. Obeticholic acid reduces bacterial translocation and inhibits intestinalinflammation in cirrhotic rats. J Hepatol 64 (2016), 1049–1057.
45. [45] Hambruch, E., Miyazaki-Anzai, S., Hahn, U., et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J Pharmacol Exp Ther 343 (2012), 556–567.
46. [46] Kinzel, O., Steeneck, C., Schlüter, T., et al. Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties. Bioorg Med Chem Lett 26 (2016), 3746–3753.
47. [47] Schwabl, P., Payer, B.A., Grahovac, J., et al. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. J Hepatol 60 (2014), 1135–1142.
48. [48] Mudaliar, S., Henry, R.R., Sanyal, A.J., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145 (2013), 574–582, e1.
49. [49] Mookerjee, R.P., Yago-Baenas, M., Mehta, G., et al. Effect of the FXR agonist obeticholic acid on portal pressure in alcoholic cirrhosis: a phase 2 proof of concept study. Hepatology, 56, 2012, 1529A.
50. [50] Gege, C., Kinzel, O., Steeneck, C., et al. Knocking on FXR's door: the “hammerhead”-structure series of FXR agonists – amphiphilic isoxazoles with potent in vitro and in vivo activities. Curr Top Med Chem 14 (2014), 2143–2158.
51. [51] Fiorucci, S., Antonelli, E., Rizzo, G., et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127 (2004), 1497–1512.
52. [52] Fickert, P., Fuchsbichler, A., Moustafa, T., et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 175 (2009), 2392–2405.
53. [53] Li, J., Wilson, A., Gao, X., et al. Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine. J Pharmacol Exp Ther 331 (2009), 234–243.
54. [54] Chen, C.A., Druhan, L.J., Varadharaj, S., et al. Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme. J Biol Chem 283 (2008), 27038–27047.
55. [55] Zhao, W., Zhang, J., Lu, Y., Wang, R., The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J 20 (2001), 6008–6016.
56. [56] Rockey, D.C., Fouassier, L., Chung, J.J., et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 27 (1998), 472–480.
57. [57] Rockey, D.C., Chung, J.J., Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest 98 (1996), 1381–1388.
58. [58] He, F., Li, J., Mu, Y., et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res 98 (2006), 192–199.
59. [59] Verbeke, L., Mannaerts, I., Schierwagen, R., et al. FXR agonist obeticholic acid reduces hepatic inflammation andfibrosis in a rat model of toxic cirrhosis. Sci Rep, 6, 2016, 33453.
60. [60] Hayashi, H., Beppu, T., Okabe, H., et al. Combined measurements of serum bile acid level and splenic volume may be useful to noninvasively assess portal venous pressure. J Gastroenterol 47 (2012), 1336–1341.
61. [61] Mannes, G.A., Thieme, C., Stellaard, F., et al. Prognostic significance of serum bile acids in cirrhosis. Hepatology 6 (1986), 50–53.
62. [62] Song, P., Zhang, Y., Klaassen, C.D., Dose-response of five bile acids on serum andliver bile Acid concentrations and hepatotoxicty in mice. Toxicol Sci 123 (2011), 359–367.
63. [63] Pak, J.M., Lee, S.S., Vasoactive effects of bile salts in cirrhotic rats: in vivo and in vitro studies. Hepatology 18 (1993), 1175–1181.